Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment.
Viswanathan L, Bachman E, Tian S, Ahluwalia N, Zhang Y, Bernstein HS, Panorchan P. Viswanathan L, et al. Among authors: panorchan p. Eur J Drug Metab Pharmacokinet. 2022 Nov;47(6):817-825. doi: 10.1007/s13318-022-00791-8. Epub 2022 Aug 29. Eur J Drug Metab Pharmacokinet. 2022. PMID: 36036885 Free PMC article. Clinical Trial.
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
Davies JC, Sermet-Gaudelus I, Naehrlich L, Harris RS, Campbell D, Ahluwalia N, Short C, Haseltine E, Panorchan P, Saunders C, Owen CA, Wainwright CE; VX16-661-115 Investigator Group. Davies JC, et al. Among authors: panorchan p. J Cyst Fibros. 2021 Jan;20(1):68-77. doi: 10.1016/j.jcf.2020.07.023. Epub 2020 Sep 21. J Cyst Fibros. 2021. PMID: 32967799 Free article. Clinical Trial.
Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial.
Davies JC, Wainwright CE, Sawicki GS, Higgins MN, Campbell D, Harris C, Panorchan P, Haseltine E, Tian S, Rosenfeld M. Davies JC, et al. Among authors: panorchan p. Am J Respir Crit Care Med. 2021 Mar 1;203(5):585-593. doi: 10.1164/rccm.202008-3177OC. Am J Respir Crit Care Med. 2021. PMID: 33023304 Free PMC article. Clinical Trial.
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
Lawitz E, Sulkowski M, Jacobson I, Kraft WK, Maliakkal B, Al-Ibrahim M, Gordon SC, Kwo P, Rockstroh JK, Panorchan P, Miller M, Caro L, Barnard R, Hwang PM, Gress J, Quirk E, Mobashery N. Lawitz E, et al. Among authors: panorchan p. Antiviral Res. 2013 Sep;99(3):214-20. doi: 10.1016/j.antiviral.2013.05.015. Epub 2013 Jun 7. Antiviral Res. 2013. PMID: 23747481 Clinical Trial.
Liver-to-plasma vaniprevir (MK-7009) concentration ratios in HCV-infected patients.
Wright DH, Caro L, Cerra M, Panorchan P, Du L, Anderson M, Potthoff A, Nachbar RB, Wagner J, Manns MP, Talal AH. Wright DH, et al. Among authors: panorchan p. Antivir Ther. 2015;20(8):843-8. doi: 10.3851/IMP2958. Epub 2015 Apr 7. Antivir Ther. 2015. PMID: 25849338 Free PMC article. Clinical Trial.
UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study.
Wang YH, Trucksis M, McElwee JJ, Wong PH, Maciolek C, Thompson CD, Prueksaritanont T, Garrett GC, Declercq R, Vets E, Willson KJ, Smith RC, Klappenbach JA, Opiteck GJ, Tsou JA, Gibson C, Laethem T, Panorchan P, Iwamoto M, Shaw PM, Wagner JA, Harrelson JC. Wang YH, et al. Among authors: panorchan p. Clin Pharmacol Ther. 2012 Jul;92(1):96-102. doi: 10.1038/clpt.2012.20. Epub 2012 Jun 6. Clin Pharmacol Ther. 2012. PMID: 22669291 Free PMC article. Clinical Trial.
Chapter 15: Live-cell single-molecule force spectroscopy.
Dobrowsky TM, Panorchan P, Konstantopoulos K, Wirtz D. Dobrowsky TM, et al. Among authors: panorchan p. Methods Cell Biol. 2008;89:411-32. doi: 10.1016/S0091-679X(08)00615-8. Methods Cell Biol. 2008. PMID: 19118684